Cite
Wohlschlager T, Scheffler K, Forstenlehner IC, et al. Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals. Nat Commun. 2018;9(1):1713doi: 10.1038/s41467-018-04061-7.
Wohlschlager, T., Scheffler, K., Forstenlehner, I. C., Skala, W., Senn, S., Damoc, E., Holzmann, J., & Huber, C. G. (2018). Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals. Nature communications, 9(1), 1713. https://doi.org/10.1038/s41467-018-04061-7
Wohlschlager, Therese, et al. "Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals." Nature communications vol. 9,1 (2018): 1713. doi: https://doi.org/10.1038/s41467-018-04061-7
Wohlschlager T, Scheffler K, Forstenlehner IC, Skala W, Senn S, Damoc E, Holzmann J, Huber CG. Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals. Nat Commun. 2018 Apr 30;9(1):1713. doi: 10.1038/s41467-018-04061-7. PMID: 29712889; PMCID: PMC5928108.
Copy
Download .nbib